ADMA Biologics

ADMA is a late-stage biopharmaceutical company that develops, manufactures and intends to commercialize specialty plasma-based biologics for the treatment and prevention of Primary Immune Deficiency Disease (PIDD) and certain infectious diseases. ADMA's mission is to develop and commercialize plasma-derived, human immune globulins targeted to niche patient populations for the treatment and prevention of certain infectious diseases. The target patient populations include immune-compromised individuals who suffer from an underlying immune deficiency disease, or who may be immune-compromised for medical reasons. ADMA’s lead product candidate, RI-002, has completed a Phase III clinical trial in patients with PIDD and has met the primary endpoint. A BLA for RI-002 was accepted by the FDA on September 18, 2015. The company has received U.S. Patent 9,107,906.
Type
Public
HQ
Ramsey, US
Founded
2004
Employees
72 (est)+20%

Key People at ADMA Biologics

Dov Goldstein

Dov Goldstein

Director
Bryant E. Fong

Bryant E. Fong

Director
James Mond

James Mond

Chief Scientific and Medical Officer
Brian Lenz

Brian Lenz

Vice President, Chief Financial Officer
Eric I. Richman

Eric I. Richman

Director & Chairperson
Jerrold B. Grossman

Jerrold B. Grossman

Founder and Vice Chairman

ADMA Biologics Locations

Ramsey, US

ADMA Biologics Metrics

ADMA Biologics Summary

Founding Date

2004

Market capitalization

$69.6 M

Closing share price

$5.41

ADMA Biologics Market Value History

ADMA Biologics News

ADMA Biologics Company Life

You may also be interested in